cabozantinib

This page shows the latest cabozantinib news and features for those working in and with pharma, biotech and healthcare.

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

Bristol Myers Squibb (BMS) and Exelixis also recently revealed new analyses from a phase 3 study of their Opdivo (nivolumab) and Cabometyx (cabozantinib) combination in first-line, advanced RCC.

Latest news

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

and Exelixis’ tyrosine kinase inhibitor Cabometyx (cabozantinib).
BMS eyes approval for second Opdivo combo in kidney cancer

plus tyrosine kinase inhibitor (TKI) Cabometyx (cabozantinib) compared to Pfizer’s older drug Sutent (sunitinib).
Revenue growth at Ipsen numbs pain of palovarotene calamity

The French speciality drugmaker posted 2.58bn in sales for the full-year, up nearly 15%, thanks to another strong performance for cancer drugs Somatuline (lanreotide) and Cabometyx (cabozantinib) as well
Exelixis bounces back with new prostate cancer data

It is also testing cabozantinib in combination with Tecentriq in another setting – previously untreated HCC. ... Exelixis intends to file the cabozantinib/Tecentriq combination with the FDA for accelerated approval in metastatic CRPC by 2021.
Merck bulks up in cancer with $2.2bn Peloton buy

with Exelixis/Ipsen’s multikinase inhibitor Cabometyx (cabozantinib).

More from news
Approximately 4 fully matching, plus 14 partially matching documents found.

Latest Intelligence

Charting a course for expansion

Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.
Deal Watch March 2016

marketed product Cometriq (cabozantinib). ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?

In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... Also, the secondary endpoint, response rate, was higher and more significant with cabozantinib.

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

MEDICAL WRITER - HOME WORKING: Salary TBC

SENIOR MEDICAL WRITER: Salary TBC

ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER: Salary TBC

Senior Account Director - Med Comms Agency: Salary TBC

SENIOR ACCOUNT MANAGER - MEDICAL COMMUNICATIONS: Salary TBC

PMHub

Add my company

An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial: What key things do you need to remember to reach patients living with Alzheimer’s disease?...
Integrating competitive intelligence into business development, licensing and M&A strategy: The advantages of partnering with a competitive intelligence or knowledge management team...
Reaching patients and HCPs during the pandemic: COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...